Tetrabenazine
Tetrabenazine is a monoamine-depleting agent that reversibly inhibits vesicular monoamine transporter 2 (VMAT2), blocking the packaging of dopamine, serotonin, and norepinephrine into synaptic vesicles and depleting presynaptic monoamine stores. It is approved for the treatment of chorea associated with Huntington's disease, and is also used for hemiballismus, tardive dyskinesia, and other hyperkinetic movement disorders. Central dopamine depletion reduces involuntary movements but can cause depression, sedation, and parkinsonism as adverse effects.
Peso molecular
317,4000 g/mol
LogP
2,90
TPSA
38,80 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Estructura 2D
Cite this structure
Embed this structure
SMILES
COc1cc2c(cc1OC)C1CC(=O)C(CC(C)C)CN1CC2
InChI
InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3
Molecular Formula
C19H27NO3
HBD / HBA
- / 4
Enlaces Rotables
4
Átomos Pesados
23
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
Tetrabenazine is a monoamine-depleting agent that reversibly inhibits vesicular monoamine transporter 2 (VMAT2), blocking the packaging of dopamine, serotonin, and norepinephrine into synaptic vesicles and depleting presynaptic monoamine stores. It is approved for the treatment of chorea associated with Huntington's disease, and is also used for hemiballismus, tardive dyskinesia, and other hyperkinetic movement disorders. Central dopamine depletion reduces involuntary movements but can cause depression, sedation, and parkinsonism as adverse effects.
Yes, Tetrabenazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL117785. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6018. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tetrabenazine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tetrabenazine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tetrabenazine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tetrabenazine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tetrabenazine"></drugfyi-drug>